Integra Lifesciences Holdings (IART) Other Non-Current Liabilities (2009 - 2026)

Integra Lifesciences Holdings has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $194.4 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 23.21% year-over-year to $194.4 million; the TTM figure through Jun 2026 stood at $194.4 million (down 23.21% YoY), while the FY2025 annual figure was $204.3 million, up 39.69% from the prior year.
• Other Non-Current Liabilities came in at $194.4 million for Q2 2026 at Integra Lifesciences Holdings, down from $195.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $253.2 million in Q2 2025 to a low of $63.7 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $159.7 million, with a median of $154.1 million recorded in 2023.
• Year-over-year, Other Non-Current Liabilities plunged 56.24% in 2022 and soared 123.37% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $138.5 million in 2022, then jumped by 44.36% to $199.9 million in 2023, then fell by 26.86% to $146.2 million in 2024, then surged by 39.69% to $204.3 million in 2025, then slipped by 4.84% to $194.4 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $194.4 million in Q2 2026, $195.6 million in Q1 2026, and $204.3 million in Q4 2025.